Doxofylline (Standard)
Doxofylline (Standard) is the analytical standard of Doxofylline. This product is intended for research and analytical applications. Doxofylline is an orally active PDE IV inhibitor and A1AR antagonist. Doxofylline reduces inflammation in epithelial cells via inhibiting mitochondrial ROS production and amelioration of multiple cellular pathways (NLRP3-TXNIP inflammasome activation). Doxophylline can be used in studies of asthma, chronic obstructive pulmonary disease, and bronchospasm.
Nos produits utilisent uniquement pour la recherche. Nous ne vendons pas aux patients.
- Pureté : 98%
- CAS No.: 69975-86-6
- Formule: C11H14N4O4
- Masse moléculaire:266.25
-
Stockage:
Please store the product under the recommended conditions in the Certificate of Analysis.
To place orders, for customer services and technical support, please contact: MedChemExpress USA
Tel: 609-228-6898 E-mail: [email protected] [email protected]
-
Product Information
-
Chemical Information
- Pureté et documentation
-
Help & FAQs
-
HY-B0004
DoxofyllinePDE IV Inhibitor/A1AR Antagonist -
HY-B0128
DiphyllinePDE Inhibitor -
HY-B0312
DipyridamolePDE Inhibitor -
HY-15455
RoflumilastPDE4 Inhibitor -
HY-B0128R
Diphylline (Standard)PDE Inhibitor -
HY-17464
CilostazolPDE3 Inhibitor -
HY-B0715
PentoxifyllinePDE Inhibitor -
HY-12318
IBMXPDE Inhibitor -
HY-N0014
IcariinPPAR Activator -
HY-16900
RolipramPDE4 Inhibitor -
HY-B0809
TheophyllinePDE Inhibitor -
HY-14252
Milrinone
Product Information
Information
Application
The compound is the grade of analytical standard, which is the reference standard supplied assay. It is commonly used in qualitative, quantitative and methodological research experiments in HPLC, GC and MS.
Chemical Information
-
CAS No. 69975-86-6
-
Masse moléculaire 266.25
-
Formule C11H14N4O4
-
SMILES
O=C(N1C)N(C)C2=C(N(CC3OCCO3)C=N2)C1=O
-
Livraison
Room temperature in continental US; may vary elsewhere.
-
Stockage
Please store the product under the recommended conditions in the Certificate of Analysis.
Pureté et documentation
Références
[1]. Jiao P, et al. The protective effect of doxofylline against lipopolysaccharides (LPS)-induced activation of NLRP3 inflammasome is mediated by SIRT1 in human pulmonary bronchial epithelial cells. Artif Cells Nanomed Biotechnol. 2020 Dec;48(1):687-694. [Content Brief]
[2]. Riffo-Vasquez Y, et al. Doxofylline, a novofylline inhibits lung inflammation induced by lipopolysacharide in the mouse. Pulm Pharmacol Ther. 2014 Apr;27(2):170-8. [Content Brief]
[3]. Shukla D, et al. Doxofylline: a promising methylxanthine derivative for the treatment of asthma and chronic obstructive pulmonary disease. Expert Opin Pharmacother. 2009 Oct;10(14):2343-56. [Content Brief]
Calculators
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
Doxofylline (Standard) Related Classifications
HY-B0004R Related Classifications
Powered by Bioz